Please enable JavaScript to continue using this application.

Compare $PTGX vs $TWST | Chartloom

Compare

$PTGX vs $TWST

Protagonist Therapeutics Inc · Twist Bioscience Corp

PTGX

Protagonist Therapeutics Inc

TWST

Twist Bioscience Corp

Compare $PTGX vs $TWST

Comparing Protagonist Therapeutics Inc and Twist Bioscience Corp

PTGXProtagonist Therapeutics Inc

TWSTTwist Bioscience Corp

PTGXProtagonist Therapeutics Inc

Market cap

$9.24B

P/E (TTM)

123.10x

Forward P/E (NTM)

77.71x

Forward P/S (NTM)

23.74x

Rev growth (TTM)

34.8%

YTD performance

64.9%

52W performance

120.1%

FCF yield

1.4%

TWSTTwist Bioscience Corp

Market cap

$9.95B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

18.83x

Rev growth (TTM)

19.2%

YTD performance

393.3%

52W performance

387.3%

FCF yield

-1.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PTGX

TWST

Detailed metrics comparison

PTGX

Protagonist Therapeutics Inc

TWST

Twist Bioscience Corp

Market Cap

PTGX$9.24B

TWST$9.95B

Enterprise Value

PTGX$8.82B

TWST$9.83B

Price

PTGX$143.73

TWST$159.78

P/E Ratio

PTGX123.10x

TWSTN/A

P/S Ratio

PTGX32.78x

TWST23.04x

EV/Sales

PTGX31.29x

TWST22.77x

EV/EBITDA

PTGX140.17x

TWST0.00x

P/B Ratio

PTGX10.77x

TWST27.87x

P/FCF Ratio

PTGX70.79x

TWSTN/A

EV/FCF

PTGX67.57x

TWST-100.10x

PEG Ratio

PTGX2.95x

TWSTN/A

Forward P/E (NTM)

PTGX77.71x

TWSTN/A

Forward P/S (NTM)

PTGX23.74x

TWST18.83x

Revenue (TTM)

PTGX$282M

TWST$432M

Revenue Growth (YoY)

PTGX34.8%

TWST19.2%

Forward Rev Growth

PTGX-70.6%

TWST15.0%

Gross Margin (TTM)

PTGX0.0%

TWST52.0%

Operating Margin (TTM)

PTGX20.7%

TWST0.0%

EBITDA Margin (TTM)

PTGX21.2%

TWST-26.0%

Net Margin (TTM)

PTGX29.4%

TWST-31.7%

FCF Margin (TTM)

PTGX46.3%

TWST-22.7%

Net Income (TTM)

PTGX$83M

TWST$-137M

FCF (TTM)

PTGX$131M

TWST$-98M

EPS (TTM)

PTGX$1.17

TWST-$2.19

ROE (TTM)

PTGX12.0%

TWST-2989.0%

ROA (TTM)

PTGX11.2%

TWST-2080.0%

ROIC (TTM)

PTGX12.0%

TWST-2989.0%

Cash

PTGX$420M

TWST$117M

Debt

PTGX$0

TWST$0

Net Cash/Debt

PTGX$420M

TWST$117M

Current Ratio (TTM)

PTGX21.71x

TWST2.67x

Quick Ratio (TTM)

PTGX21.58x

TWST2.30x

Debt/Equity (TTM)

PTGX0.00x

TWST0.00x

Debt/Assets (TTM)

PTGX0.0%

TWST0.0%

Interest Coverage (TTM)

PTGXN/A

TWSTN/A

Net Debt/EBITDA (TTM)

PTGX0.00x

TWST0.00x

Beta

PTGX1.19

TWST2.17

52W Performance

PTGX120.1%

TWST387.3%

YTD Performance

PTGX64.9%

TWST393.3%

% from 52W High

PTGX-10.6%

TWST-27.3%

% from 52W Low

PTGX119.2%

TWST585.8%

Asset Turnover (TTM)

PTGX0.38x

TWST0.66x

FCF Yield (TTM)

PTGX1.4%

TWST-1.0%

Earnings Yield (TTM)

PTGX0.9%

TWST-1.4%

Dividend Yield (TTM)

PTGXN/A

TWSTN/A

Rule of 40

PTGX81.1

TWST-3.6

EV/GP/RG

PTGXN/A

TWST1.94

Ticker research

View PTGX research View TWST research

Metric	PTGX Protagonist Therapeutics Inc	TWST Twist Bioscience Corp
Market & Valuation
Market Cap	$9.24B	$9.95B
Enterprise Value	$8.82B	$9.83B
Price	$143.73	$159.78
P/E Ratio	123.10x	N/A
P/S Ratio	32.78x	23.04x
EV/Sales	31.29x	22.77x
EV/EBITDA	140.17x	0.00x
P/B Ratio	10.77x	27.87x
P/FCF Ratio	70.79x	N/A
EV/FCF	67.57x	-100.10x
PEG Ratio	2.95x	N/A
Forward P/E (NTM)	77.71x	N/A
Forward P/S (NTM)	23.74x	18.83x
Revenue & Growth
Revenue (TTM)	$282M	$432M
Revenue Growth (YoY)	34.8%	19.2%
Forward Rev Growth	-70.6%	15.0%
Profitability
Gross Margin (TTM)	0.0%	52.0%
Operating Margin (TTM)	20.7%	0.0%
EBITDA Margin (TTM)	21.2%	-26.0%
Net Margin (TTM)	29.4%	-31.7%
FCF Margin (TTM)	46.3%	-22.7%
Net Income (TTM)	$83M	$-137M
FCF (TTM)	$131M	$-98M
EPS (TTM)	$1.17	-$2.19
ROE (TTM)	12.0%	-2989.0%
ROA (TTM)	11.2%	-2080.0%
ROIC (TTM)	12.0%	-2989.0%
Financial Health
Cash	$420M	$117M
Debt	$0	$0
Net Cash/Debt	$420M	$117M
Current Ratio (TTM)	21.71x	2.67x
Quick Ratio (TTM)	21.58x	2.30x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	2.17
52W Performance	120.1%	387.3%
YTD Performance	64.9%	393.3%
% from 52W High	-10.6%	-27.3%
% from 52W Low	119.2%	585.8%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.66x
FCF Yield (TTM)	1.4%	-1.0%
Earnings Yield (TTM)	0.9%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	-3.6
EV/GP/RG	N/A	1.94
Ticker research	View PTGX research	View TWST research

Valuation

P/E Ratio

PTGX

123.10x

P/S Ratio

TWST

23.04x

PTGX

32.78x

EV/FCF

TWST

-100.10x

PTGX

67.57x

Growth & revenue

Revenue Growth TTM

PTGX

34.8%

TWST

19.2%

Forward Revenue Growth

TWST

15.0%

PTGX

-70.6%

Profitability & performance

Gross Margin

TWST

52.0%

PTGX

0.0%

ROE

PTGX

12.0%

TWST

-2989.0%

FCF Yield %

PTGX

1.4%

TWST

-1.0%

52-Week Performance

TWST

387.3%

PTGX

120.1%

Detailed metrics comparison

PTGX

Protagonist Therapeutics Inc

TWST

Twist Bioscience Corp

Market Cap

PTGX$9.24B

TWST$9.95B

Enterprise Value

PTGX$8.82B

TWST$9.83B

Price

PTGX$143.73

TWST$159.78

P/E Ratio

PTGX123.10x

TWSTN/A

P/S Ratio

PTGX32.78x

TWST23.04x

EV/Sales

PTGX31.29x

TWST22.77x

EV/EBITDA

PTGX140.17x

TWST0.00x

P/B Ratio

PTGX10.77x

TWST27.87x

P/FCF Ratio

PTGX70.79x

TWSTN/A

EV/FCF

PTGX67.57x

TWST-100.10x

PEG Ratio

PTGX2.95x

TWSTN/A

Forward P/E (NTM)

PTGX77.71x

TWSTN/A

Forward P/S (NTM)

PTGX23.74x

TWST18.83x

Revenue (TTM)

PTGX$282M

TWST$432M

Revenue Growth (YoY)

PTGX34.8%

TWST19.2%

Forward Rev Growth

PTGX-70.6%

TWST15.0%

Gross Margin (TTM)

PTGX0.0%

TWST52.0%

Operating Margin (TTM)

PTGX20.7%

TWST0.0%

EBITDA Margin (TTM)

PTGX21.2%

TWST-26.0%

Net Margin (TTM)

PTGX29.4%

TWST-31.7%

FCF Margin (TTM)

PTGX46.3%

TWST-22.7%

Net Income (TTM)

PTGX$83M

TWST$-137M

FCF (TTM)

PTGX$131M

TWST$-98M

EPS (TTM)

PTGX$1.17

TWST-$2.19

ROE (TTM)

PTGX12.0%

TWST-2989.0%

ROA (TTM)

PTGX11.2%

TWST-2080.0%

ROIC (TTM)

PTGX12.0%

TWST-2989.0%

Cash

PTGX$420M

TWST$117M

Debt

PTGX$0

TWST$0

Net Cash/Debt

PTGX$420M

TWST$117M

Current Ratio (TTM)

PTGX21.71x

TWST2.67x

Quick Ratio (TTM)

PTGX21.58x

TWST2.30x

Debt/Equity (TTM)

PTGX0.00x

TWST0.00x

Debt/Assets (TTM)

PTGX0.0%

TWST0.0%

Interest Coverage (TTM)

PTGXN/A

TWSTN/A

Net Debt/EBITDA (TTM)

PTGX0.00x

TWST0.00x

Beta

PTGX1.19

TWST2.17

52W Performance

PTGX120.1%

TWST387.3%

YTD Performance

PTGX64.9%

TWST393.3%

% from 52W High

PTGX-10.6%

TWST-27.3%

% from 52W Low

PTGX119.2%

TWST585.8%

Asset Turnover (TTM)

PTGX0.38x

TWST0.66x

FCF Yield (TTM)

PTGX1.4%

TWST-1.0%

Earnings Yield (TTM)

PTGX0.9%

TWST-1.4%

Dividend Yield (TTM)

PTGXN/A

TWSTN/A

Rule of 40

PTGX81.1

TWST-3.6

EV/GP/RG

PTGXN/A

TWST1.94

Ticker research

View PTGX research View TWST research

Metric	PTGX Protagonist Therapeutics Inc	TWST Twist Bioscience Corp
Market & Valuation
Market Cap	$9.24B	$9.95B
Enterprise Value	$8.82B	$9.83B
Price	$143.73	$159.78
P/E Ratio	123.10x	N/A
P/S Ratio	32.78x	23.04x
EV/Sales	31.29x	22.77x
EV/EBITDA	140.17x	0.00x
P/B Ratio	10.77x	27.87x
P/FCF Ratio	70.79x	N/A
EV/FCF	67.57x	-100.10x
PEG Ratio	2.95x	N/A
Forward P/E (NTM)	77.71x	N/A
Forward P/S (NTM)	23.74x	18.83x
Revenue & Growth
Revenue (TTM)	$282M	$432M
Revenue Growth (YoY)	34.8%	19.2%
Forward Rev Growth	-70.6%	15.0%
Profitability
Gross Margin (TTM)	0.0%	52.0%
Operating Margin (TTM)	20.7%	0.0%
EBITDA Margin (TTM)	21.2%	-26.0%
Net Margin (TTM)	29.4%	-31.7%
FCF Margin (TTM)	46.3%	-22.7%
Net Income (TTM)	$83M	$-137M
FCF (TTM)	$131M	$-98M
EPS (TTM)	$1.17	-$2.19
ROE (TTM)	12.0%	-2989.0%
ROA (TTM)	11.2%	-2080.0%
ROIC (TTM)	12.0%	-2989.0%
Financial Health
Cash	$420M	$117M
Debt	$0	$0
Net Cash/Debt	$420M	$117M
Current Ratio (TTM)	21.71x	2.67x
Quick Ratio (TTM)	21.58x	2.30x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	2.17
52W Performance	120.1%	387.3%
YTD Performance	64.9%	393.3%
% from 52W High	-10.6%	-27.3%
% from 52W Low	119.2%	585.8%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.66x
FCF Yield (TTM)	1.4%	-1.0%
Earnings Yield (TTM)	0.9%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	-3.6
EV/GP/RG	N/A	1.94
Ticker research	View PTGX research	View TWST research